Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic ...
MiMedx Group is back in focus after analysts trimmed their fair value estimate from US$10.40 to US$9.60, a modest reset that still reflects a structured view of the story rather than a wholesale ...
Fintel on MSN
Citizens Initiates Coverage of MiMedx Group (MDXG) with Market Outperform Recommendation
Fintel reports that on February 23, 2026, Citizens initiated coverage of MiMedx Group (NasdaqCM:MDXG) with a Market Outperform recommendation. Analyst Price Forecast Suggests 105.18% Upside As of ...
MiMedx Group, Inc. (Nasdaq: MDXG) ('MIMEDX” or the 'Company”) today announced that it will report its operating and financial ...
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company’s products include ML-007C-MA, ...
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results